Tuesday, 15 Oct 2019

You are here

Combination or Monotherapy Tocilizumab in Rheumatoid Arthritis

Several rheumatoid arthritis studies have shown that tocilizumab (TCZ) may be as effective as monotherapy when compared to combination therapy (methotrexate plus TCZ), including the ACT-RAY, ACT-SURE and FUNCTION clinical trials.

But it is still unclear if it is prudent to initiate TCZ treatment in RA as monotherapy or in combination with a DMARD or MTX.  The SURPRISE study is a 2-year, randomized trial of 223 active RA patients with an incomplete response to MTX who either add TCZ to MTX or switch from MTX TCZ monotherapy.  

At week 24, DAS28 (and CDAI, SDAI) remission rates were higher in those with combination TCZ (70 vs 55%) compared to TCZ monotherapy.  The ACR20/50/70 the differences between the two treatment groups were not significant, although there was a trend towards superiority of TCZ added to MTX to TCZ switched from MTX. X-ray benefits were also greater in those on combination MTX and TCZ, with X-ray progression being worse in those on TCZ monotherapy (15% vs 7%).

Overall, in those RA patients with an inadequate response to methotrexate, tocilizumab added to methotrexate more rapidly suppressed inflammation than tocilizumab switched from methotrexate, leading to superior clinical efficacy and prevention of joint destruction.

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Biologics Lead the Way in Drug Price Increases

Reuters has reported the results of a recent Institute for Clinical and Economic Review (ICER) analysis showing that biologics, especially Humira and Rituxan, are leading the way in the cost of drugs in the USA. All told, Humira and Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. drug spending. ICER said their analysis points to price hikes that were more than twice the rate of medical inflation and were not warranted by any new clinical evidence.

Ustekinumab Efficacy in Ulcerative Colitis

The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.

FDA Approves Rituximab for Children with GPA

The U.S. Food and Drug Administration has approved Rituxan (rituximab) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids. This is the first approved treatment for children with vasculitis.

Anakinra Shows Benefits in Cytokine Storm

The interleukin (IL)-1 receptor antagonist anakinra (Kineret) showed promise in critically ill children who develop the often-lethal condition known as secondary hemophagocytic lymphohistiocytosis (sHLH)/macrophage activation syndrome (MAS), a retrospective single-center study found.

 

Prior Authorizations Delay Care in Rheumatology

Physicians who believe their patients' health is negatively affected by insurers' demands for prior authorization, and the delays that often result, will find that opinion vindicated by a new study of rheumatology care: when permission had to be sought from insurers to provide intravenous drugs, average time to begin treatment was longer and patients had twice the corticosteroid exposure, a single-center analysis found.